The American Cancer Society rolls out updated screening recommendations for prostate cancer, that includes every 2 year PSA beginning at age 50 for standard risk and 45 for high risk (e.g. Black patients).
A randomized trial suggests an alternate dasatinib dosing (100 mg daily on weekdays) is non-inferior with regards to MMR at 2 years compared to 100 mg daily dosing.
Finally, the CHARGE index appears prognostic for PFS in multiple myeloma treated with Bispecific T-cell therapies.
Download the Oncology Learning Companion: https://www.kelleycpharmd.com/learning-oncology-companion-oncopharm
Altri episodi di "OncoPharm"



Non perdere nemmeno un episodio di “OncoPharm”. Iscriviti all'app gratuita GetPodcast.








